RT Journal Article
T1 Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
A1 Perez-de-Llano, Luis A
A1 Cosio, Borja G
A1 Domingo, Christian
A1 Urrutia, Isabel
A1 Bobolea, Irina
A1 Valero, Antonio
A1 Entrenas-Costa, Luis M
A1 Quirce, Santiago
A1 Barranco, Pilar
A1 Marina-Malanda, Nuria
A1 Prieto-Andres, Luis
A1 Alvarez-Gutierrez, Francisco J
K1 Asthma
K1 Asthma management
K1 Omalizumab
K1 Reslizumab
K1 Severe asthma
AB Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies. To evaluate the efficacy and safety of weight-based intravenous reslizumab dosing in patients who have previously failed therapy with omalizumab. We carried out a 24-week prospective, multicenter, open-label, single-group, self-controlled study in patients with severe eosinophilic asthma who had previously failed to respond to omalizumab. The main objective was to determine whether treatment with reslizumab significantly improved asthma symptoms assessed by the Asthma Control Test (ACT) at week 24. Secondary objectives were to evaluate symptoms at weeks 4 and 12, change in FEV1 at week 24, and the incidence of severe exacerbations over the study period. Twenty-nine patients (62.1% women, median age, 50.8 years) were included in the study. The median ACT score significantly increased from 13.0 (interquartile range, 8.0-18.0) at baseline to 21.0 (interquartile range, 14.0-24.0) at 24 weeks (P = .002). Only 2 of 29 patients developed at least 1 severe exacerbation during follow-up and none of them required hospitalization. Overall, 15 of 25 patients (60%) were considered as being controlled (ACT score of ≥20 and no exacerbations) at week 24. The percentage of patients who were receiving daily systemic corticosteroids significantly decreased from 72.4% to 52.0% (P = .019). Adverse events were mostly moderate and within the range of previously reported side effects with reslizumab. Reslizumab is an effective and safe option for patients with severe eosinophilic asthma and a history of omalizumab failure.
PB Elsevier
YR 2019
FD 2019-01-04
LK http://hdl.handle.net/10668/13454
UL http://hdl.handle.net/10668/13454
LA en
NO Pérez de Llano LA, Cosío BG, Domingo C, Urrutia I, Bobolea I, Valero A, et al. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2277-2283.e2
DS RISalud
RD Jul 31, 2025